Review of tocilizumab in the treatment of rheumatoid arthritis
Yasuaki OkudaDepartment of Internal Medicine, Center for Rheumatic Diseases, Dohgo Spa Hospital, Matsuyama-city, Ehime, JapanAbstract: Constitutively overproduced in proliferating synovial tissues, interleukin-6 (IL-6) is deeply involved in the pathology of rheumatoid arthritis (RA). Tocilizumab is...
Guardado en:
Autor principal: | Yasuaki Okuda |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e217bcd505c740e298f53ae3f08eae46 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Tocilizumab induced acquired factor XIII deficiency in patients with rheumatoid arthritis.
por: Sho Mokuda, et al.
Publicado: (2013) -
Monoclonal antibodies in rheumatoid arthritis: comparative effectiveness of tocilizumab with tumor necrosis factor inhibitors
por: Tanaka T, et al.
Publicado: (2014) -
Infliximab in the treatment of rheumatoid arthritis
por: A Perdriger
Publicado: (2009) -
Tocilizumab in refractory rheumatoid arthritis: long-term efficacy, safety, and tolerability beyond 2 years
por: Farah Z, et al.
Publicado: (2016) -
Dynamic Contrast-Enhanced MRI Confirms Rapid And Sustained Improvement Of Rheumatoid Arthritis Induced By Tocilizumab Treatment: An Italian Multicentre Study
por: Cimmino MA, et al.
Publicado: (2020)